For example, CD73 inhibitors may be beneficial in cancer by decreasing adenosine production by regulatory T cells and thus augmenting the ability of effector T cells to inhibit tumor growth (Mandapathil et al. 2010a,b; Yegutkin et al. 2011) and may be beneficial in chronic kidney disease and angiotensin II-mediated hypertension (Zhang et al. 2013). Here, NT5E is linked to cancer.